On June 14, ViiV Healthcare announced positive topline results from its Phase III...
ViiV ups the ante with positive topline data for its second two-drug HIV combo
On June 14, ViiV Healthcare announced positive topline results from its Phase III GEMINI 1 and GEMINI 2 studies.
EHA 2018: can biosimilars be implemented worldwide to promote sustainability?
An educational session (funded by a grant from Sandoz) entitled ‘Biosimilars in Hematology: Plotting the Course to Long-Term Sustainability’ at this year’s European Hematology Association (EHA) annual meeting presented evidence of the need for biosimilars to achieve sustainable healthcare innovation.
Eli Lilly’s Olumiant: how will it far among JAK inhibitors?
On June 1, Eli Lilly’s Olumiant (baricitinib) 2mg tablets received FDA approval for adult patients with moderately to severely active rheumatoid arthritis (RA) following a complete response letter from the FDA the previous year.
Telstar Presents Versatile Process Analyser Lyosensing
Lyosensing is an in-line process analyser based on the application of a quadrupole mass spectrometer system, a non-invasive technique capable of performing quantitative real-time measurements during freeze-drying processes.
ASCO 2018: Roche discusses TMB as a predictive biomarker for NSCLC
Data from B-F1RST (NCT02848651), the first prospective study of blood tumor mutational burden (bTMB) as a biomarker for Roche’s Tecentriq in non-small cell lung cancer (NSCLC), were presented on the final morning of this year’s American Society of Clinical Oncology (ASCO) annual meeting.
After positive vaccine study, VBI looks to untapped congenital CMV market
Last month, VBI Vaccines Inc. announced positive top-line results from a randomized Phase I clinical trial of VBI-1501, its experimental cytomegalovirus (CMV) vaccine candidate.
Shorter antibiotic courses have health benefits but more evidence needed
An investigator-sponsored clinical trial presented at the recent European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Madrid, Spain indicated a seven-day antibiotic course delivered similar outcomes to a 14-day course for Gram-negative bacteremia.
G protein-coupled receptor signaling set to dominate women’s health therapy market
Health disorders in women can be caused by many abnormalities in the body and represent a broad therapy area.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.